| Patient | Jacqueline Mary du Pré |
|---|---|
| Date of birth | 1998-01-26 |
| Identifiers | MRN HR-ML039-SYN; SSN (made up) 000-39-7062 |
| Document date | 2026-03-23 |
| Author | Imogen Thackeray-Osei, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Diagnosis visit: MRI and lumbar puncture results and the neurology consultation. [S]
Ms. du Pré returns two weeks after her first visit. MRI of the brain and spine three days after that visit showed lesions typical of multiple sclerosis in the brain and the spinal cord, including an enhancing lesion at C3 to C4 that explains her hands, and the lumbar puncture a week ago showed oligoclonal bands in the spinal fluid only. Aquaporin-4 antibody was negative. She was seen today by Dr. Lindgren-Achebe. The numbness and clumsiness in her fingers are no better; she has practiced for only a few minutes at a time this week and has cancelled two more concerts. The electric feeling down her back when she bends her head continues. She is tired by mid-afternoon. She asked what multiple sclerosis will mean for her playing, and whether she can still have children. [S]
| Element | Detail |
|---|---|
| Diagnosis | Relapsing-remitting multiple sclerosis, active: dissemination in space and time on MRI and CSF-specific oligoclonal bands |
| Tests since the first visit | MRI of the brain and cervical and thoracic spine with gadolinium; lumbar puncture; aquaporin-4 antibody; HIV and syphilis serology |
| Symptoms | Numb, clumsy fingers, worse on the left; Lhermitte's sign; fatigue |
| Her questions | Whether she will play again; whether she can have children; how treatment will fit around concerts and teaching |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired by mid-afternoon; no fever; weight steady |
| Neurological | Positive | Numbness and clumsiness of the fingers; Lhermitte's sign; no weakness of the legs, imbalance or visual change |
| Genitourinary | Negative | No urinary urgency or burning; last period three weeks ago |
| Eyes | Negative | No blurred vision or pain on moving the eyes |
| Musculoskeletal | Negative | No back pain |
| Psychiatric | Positive | Frightened and tearful about her playing; PHQ-9 7, GAD-7 6; no thoughts of self-harm |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Cholecalciferol (vitamin D3) 4000 unit (100 microgram) oral capsule, one capsule by mouth daily | One capsule daily | Oral route | 2026-03-23 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-03-23 | Body height | 173 | cm | S |
| 2026-03-23 | Body weight | 63.4 | kg | S |
| 2026-03-23 | Body mass index (BMI) [Ratio] | 21.2 | kg/m2 | S |
| 2026-03-23 | Systolic blood pressure | 114 | mm[Hg] | S |
| 2026-03-23 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-03-23 | Heart rate | 76 | /min | S |
| 2026-03-23 | Respiratory rate | 14 | /min | S |
| 2026-03-23 | Body temperature | 36.7 | Cel | S |
| 2026-03-23 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-03-23 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 16 | ng/mL | Below 20 ng/mL deficient; 20 to 29 insufficient | Low | S |
| 2026-03-23 | IgG [Mass/volume] in Serum or Plasma | 1080 | mg/dL | 700-1600 mg/dL | Normal | S |
| 2026-03-23 | IgM [Mass/volume] in Serum or Plasma | 124 | mg/dL | 40-230 mg/dL | Normal | S |
| 2026-03-23 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | {score} | S | ||
| 2026-03-23 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 6 | {score} | S | ||
| 2026-03-23 | 9-Hole Pegboard Dexterity Test Time Hand - right [NIH Toolbox] | 24.5 | s | S | ||
| 2026-03-23 | 9-Hole Pegboard Dexterity Test Time Hand - left [NIH Toolbox] | 31 | s | S |
Vital signs recorded on 2026-03-23; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 63.4 kg; blood pressure 114/72, pulse 76 |
| Cranial nerves | Normal; no nystagmus; visual acuity and fields normal |
| Neurological | Reduced vibration and joint position sense in the fingers of both hands, worse on the left, with mild wandering of the left fingers when the eyes are closed; light touch reduced in the fingertips; finger and wrist strength 5 out of 5 except finger abduction 4+ on the left; brisk reflexes in the arms; Lhermitte's sign present; gait and balance normal. Nine-hole peg test 24.5 seconds right, 31.0 seconds left. EDSS 2.0 |
| Psychiatric | Warm and expressive; anxious; asks exact questions |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Numbness, tingling and loss of position sense in the fingers of both hands for three weeks, worse on the left, with clumsiness that makes her lose her place on the fingerboard, an electric feeling down the spine on bending the neck (Lhermitte's sign), and fatigue; a similar month of tingling in the fingers 18 months ago settled on its own. A lesion of the cervical spinal cord must be found: MRI of the brain and spine with contrast booked this week | resolved | confirmed | R20.2 | S — Synthetic presenting problem anchored to her documented loss of sensation in her fingers and fatigue. Superseded by the diagnosis at the second visit. |
| Relapsing-remitting multiple sclerosis, active: a current relapse (partial cervical myelitis at C3 to C4 with sensory loss and clumsiness of the hands) after an earlier sensory episode; dissemination in space and time on MRI, with an enhancing cord lesion and an enhancing brain lesion; CSF-specific oligoclonal bands; aquaporin-4 antibody negative; meets the 2017 McDonald criteria and the 2024 revision; synthetic modern detail linked to her documented diagnosis | active | confirmed | G35.A | S — Synthetic course, imaging and laboratory detail; linked to her documented diagnosis in October 1973. |
| Vitamin D deficiency: 25-hydroxyvitamin D 16 ng/mL; replacement to correct the deficiency, not as a treatment for multiple sclerosis | active | confirmed | E55.9 | S — Synthetic finding. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | MRI of the brain and cervical and thoracic spine with gadolinium | At diagnosis | Up to date | Eleven typical brain lesions in periventricular, juxtacortical and infratentorial sites, one enhancing; enhancing C3 to C4 lesion and non-enhancing T7 lesion; central veins in most lesions |
| Laboratory | Cerebrospinal fluid: oligoclonal bands, cell count, protein | At diagnosis when it adds certainty | Up to date | Six CSF-specific oligoclonal bands; IgG index 0.86; white cells 6, protein 42 mg/dL |
| Laboratory | Mimics: vitamin B12, TSH, HIV, syphilis | At diagnosis | Up to date | B12 468 pg/mL and TSH 1.6 mIU/L at the first visit; HIV and syphilis negative |
| Laboratory | Aquaporin-4 antibody (cell-based assay) | When a myelitis or optic neuritis raises neuromyelitis optica spectrum disorder | Up to date | Negative |
| Laboratory | MOG antibody | Only when the picture suggests MOG antibody disease | Not indicated | No optic neuritis, long cord lesion or ADEM-like picture; typical MS lesions with central veins |
| Laboratory | JCV antibody | Before choosing natalizumab, and every six months while on it | Up to date | Positive, index 1.4 (drawn with the lumbar puncture); natalizumab not chosen |
| Laboratory | Hepatitis B (surface antigen, core antibody, surface antibody), varicella and measles immunity | Before anti-CD20 therapy | Up to date | Drawn with the lumbar puncture: hepatitis B surface antigen and core antibody negative, surface antibody negative (not immune); varicella IgG positive; measles immune by two recorded doses |
| Laboratory | Immunoglobulins (IgG, IgM) | At baseline and before each ocrelizumab dose | Completed today | IgG 1080 mg/dL, IgM 124 mg/dL |
| Laboratory | 25-hydroxyvitamin D | At diagnosis | Completed today | 16 ng/mL: deficient |
| Laboratory | Pregnancy test | Before steroids and before each ocrelizumab dose | Completed today | Urine pregnancy test negative |
| Medication safety | Infection screen before high-dose steroids | Before each steroid course | Completed today | Urine dipstick negative; no fever |
| Medication safety | Vaccinations before B-cell therapy | Inactivated vaccines at least two weeks before the first dose; live vaccines at least four weeks before | Completed today | PCV20, recombinant zoster dose 1 and hepatitis B dose 1 given today; no live vaccine needed |
| Examination | Hand function: nine-hole peg test, both hands | At diagnosis, after a relapse, and at each review | Completed today | 24.5 seconds right, 31.0 seconds left (typical for her age about 17 to 19 seconds) |
| Examination | Neurological examination and EDSS | At diagnosis and at each review | Completed today | Sensory loss in the fingers, mild left finger weakness, Lhermitte's sign; EDSS 2.0 |
| Referral | Occupational therapy | For any problem with hand function or fatigue | Referred | Assessment booked for next week |
| Survey | Mood and anxiety (PHQ-9, GAD-7) | At diagnosis and at each review | Completed today | PHQ-9 7 (item 9 scored 0), GAD-7 6 |
| Self-management | Pregnancy planning and contraception | At diagnosis and at each review | Completed today | Pregnancy is possible with multiple sclerosis; on ocrelizumab, conception is best planned a few months after a dose, with the neurologist; condoms for now |
| Self-management | Written information and MS specialist nurse | At diagnosis | Completed today | Written information given; nurse contact and relapse line |
Goal progress:
Immunizations given today: Pneumococcal conjugate vaccine (PCV20), before B-cell therapy; Recombinant zoster vaccine, dose 1 of 2, before B-cell therapy; Hepatitis B vaccine (adjuvanted, two-dose series), dose 1, before B-cell therapy [S]
Guideline basis: Rae-Grant A, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Neurology 2018;90(17):777-788 (PMID 29686116) (2018); Montalban X, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler 2018;24(2):96-120 (PMID 29353550) (2018); Multiple sclerosis in adults: management (NICE guideline NG220) (2022); Thompson AJ, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018;17(2):162-173 (PMID 29275977) (2017); Montalban X, et al. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol 2025;24(10):850-865 (doi:10.1016/S1474-4422(25)00270-4) (2025); Wattjes MP, et al. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol 2021;20(8):653-670 (PMID 34139157) (2021); Farez MF, et al. Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis. Neurology 2019;93(13):584-594 (PMID 31462584) (2019)
Follow-up: Methylprednisolone from tomorrow for 3 days; occupational therapy next week; ocrelizumab day 1 in three weeks. Review at the second half-dose. Call at once for new weakness, imbalance, loss of vision or bladder control. Next scheduled visit 2026-04-27: second half-dose of the first ocrelizumab course: recovery of hand function, infusion reactions, vaccination, practice and work. [S]